{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.8","upperLimit":"92.9","value":"90.2"},{"groupId":"OG001","lowerLimit":"82.9","upperLimit":"89.8","value":"86.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"369"},{"groupId":"OG001","value":"369"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nOral palonosetron\n\nDexamethasone","id":"OG000","title":"Oral Palonosteron Plus Dexamethasone"},{"description":"Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nI.V. palonosetron\n\nDexamethasone","id":"OG001","title":"I.V. Palonosetron Plus Dexamethasone"}],"paramType":"NUMBER","populationDescription":"FAS i.e. patients receiving study drugs and chemotherapy","reportingStatus":"POSTED","timeFrame":"0-24 hours","title":"Percentage of Patients With no Emesis","type":"SECONDARY","unitOfMeasure":"percentage of responders"}